{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:48:33Z","timestamp":1787676513149,"version":"build-2784847793"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.011","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:21:52Z","timestamp":1704727312000},"page":"281-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune-Pathogenesis of Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2023.12.011_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.011_bib2","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2023.12.011_bib3","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib4","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"Rognvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hoc.2023.12.011_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2023.12.011_bib7","first-page":"S4","article-title":"The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception","volume":"98 Suppl 2","author":"Dhodapkar","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.011_bib8","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib9","doi-asserted-by":"crossref","first-page":"e000734","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.hoc.2023.12.011_bib10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy specific effector T\u00a0cell response in the bone marrow of patients with preneoplastic gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20031787","article-title":"Premalignant lesions as targets for cancer vaccines","volume":"198","author":"Finn","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2023.12.011_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv Immunol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T\u00a0cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.011_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","article-title":"Designing Evolutionary Based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.hoc.2023.12.011_bib16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/bloodadvances.2017012732","article-title":"Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy","volume":"1","author":"Kini Bailur","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib17","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T\u00a0cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib18","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.011_bib21","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.011_bib22","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI82646","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.011_bib24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.011_bib25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A\u00a0niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.011_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib30","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.011_bib31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2023.12.011_bib32","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.011_bib33","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3389\/fimmu.2019.02385","article-title":"Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?","volume":"10","author":"Dhodapkar","year":"2019","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.hoc.2023.12.011_bib34","doi-asserted-by":"crossref","first-page":"e167629","DOI":"10.1172\/JCI167629","article-title":"Regulation of antigen-specific T-cell infiltration and spatial architecture in myeloma and premalignancy","volume":"133","author":"Robinson","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review","volume":"23","author":"McShane","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib36","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib37","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41375-019-0689-0","article-title":"Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma","volume":"34","author":"Maura","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.011_bib38","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2011-08-376236","article-title":"Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma","volume":"119","author":"Koduru","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.011_bib39","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood-2018-02-834689","article-title":"MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association","volume":"131","author":"Weinreb","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.011_bib41","doi-asserted-by":"crossref","first-page":"e98259","DOI":"10.1172\/jci.insight.98259","article-title":"Antigen-mediated regulation in monoclonal gammopathies and myeloma","volume":"3","author":"Nair","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.011_bib42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1084\/jem.141.3.608","article-title":"Structural, functional, and idiotypic characteristics of a phosphorylcholine-binding IgA myeloma protein of C57BL\/ka allotype","volume":"141","author":"Claflin","year":"1975","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-019-0210-z","article-title":"Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.011_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J\u00a0Pathol"},{"issue":"6501","key":"10.1016\/j.hoc.2023.12.011_bib47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aay9733","article-title":"Autoreactivity in naive human fetal B cells is associated with commensal bacteria recognition","volume":"369","author":"Chen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hoc.2023.12.011_bib48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coi.2019.01.002","article-title":"T-bet(+) B cells: A common denominator in protective and autoreactive antibody responses?","volume":"57","author":"Myles","year":"2019","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-22-0173","article-title":"Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections","volume":"4","author":"Azeem","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib50","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.011_bib51","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-20-2119","article-title":"Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120","volume":"26","author":"Dhodapkar","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.011_bib52","doi-asserted-by":"crossref","first-page":"e95367","DOI":"10.1172\/jci.insight.95367","article-title":"Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens","volume":"2","author":"Bosseboeuf","year":"2017","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib53","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","article-title":"Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia","volume":"2","author":"Kaushal","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.011_bib54","doi-asserted-by":"crossref","first-page":"eabl4644","DOI":"10.1126\/sciadv.abl4644","article-title":"Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma","volume":"8","author":"Rodriguez","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.hoc.2023.12.011_bib55","first-page":"JCO2102257","article-title":"Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma","author":"Nooka","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hoc.2023.12.011_bib57","doi-asserted-by":"crossref","first-page":"620596","DOI":"10.3389\/fimmu.2021.620596","article-title":"Treg and Oligoclonal Expansion of Terminal Effector CD8(+) T Cell as Key Players in Multiple Myeloma","volume":"12","author":"Joshua","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.011_bib58","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2023.12.011_bib59","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.011_bib61","doi-asserted-by":"crossref","first-page":"e129353","DOI":"10.1172\/jci.insight.129353","article-title":"Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer","volume":"5","author":"Bar","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.hoc.2023.12.011_bib62","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3389\/fimmu.2018.02204","article-title":"Checkpoint Inhibition in Myeloma: Opportunities and Challenges","volume":"9","author":"Costa","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.011_bib63","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.011_bib64","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T\u00a0cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.011_bib65","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T\u00a0cell exhaustion and is reversed by TIGIT inhibition","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2023.12.011_bib66","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFalpha","volume":"5","author":"Akhmetzyanova","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.011_bib67","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib68","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","article-title":"Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma","volume":"107","author":"Wang","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib69","first-page":"540","article-title":"Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR\u2212\/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma","volume":"72","author":"Brimnes","year":"2010"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.011_bib70","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.011_bib71","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4(+)PD-1(+) Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.011_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib73","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.011_bib74","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"issue":"32","key":"10.1016\/j.hoc.2023.12.011_bib75","doi-asserted-by":"crossref","first-page":"52614","DOI":"10.18632\/oncotarget.17538","article-title":"MM-BMSCs induce naive CD4+ T lymphocytes dysfunction through fibroblast activation protein alpha","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.hoc.2023.12.011_bib76","first-page":"3815","article-title":"Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in","volume":"190","author":"Ramachandran","year":"2013","journal-title":"Bone Marrow"},{"issue":"15","key":"10.1016\/j.hoc.2023.12.011_bib77","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.011_bib78","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.011_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1189\/jlb.3MR1116-468R","article-title":"Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche","volume":"102","author":"Asimakopoulos","year":"2017","journal-title":"J\u00a0Leukoc Biol"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib80","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-03-705780","article-title":"Immunoregulatory roles of versican proteolysis in the myeloma microenvironment","volume":"128","author":"Hope","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.011_bib81","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0711293105","article-title":"MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma","volume":"105","author":"Jinushi","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.hoc.2023.12.011_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1749-6632.2009.04931.x","article-title":"Harnessing CD1d-restricted T\u00a0cells toward antitumor immunity in humans","volume":"1174","author":"Neparidze","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.hoc.2023.12.011_bib83","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1073\/pnas.202491499","article-title":"T\u00a0cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells","volume":"99","author":"Dhodapkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.011_bib84","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A\u00a0reversible defect in natural killer T\u00a0cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib85","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/0008-5472.CAN-04-3337","article-title":"Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors","volume":"65","author":"Noonan","year":"2005","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.011_bib86","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific Antibodies in Multiple Myeloma: Present and Future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.011_bib87","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1084\/jem.20052136","article-title":"Enhancement of clonogenicity of human multiple myeloma by dendritic cells","volume":"203","author":"Kukreja","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.011_bib88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.011_bib89","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"16","key":"10.1016\/j.hoc.2023.12.011_bib90","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease","volume":"114","author":"Kukreja","year":"2009","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:59Z","timestamp":1760591939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001788"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-Pathogenesis of Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}